Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24, ...

Sign up for the Morning Brief email newsletter to get weekday updates from The Weather Channel and our meteorologists. One of the defining characteristics of eczema ...